Susana Banerjee
London gynaecological oncologist who led RAMP 201, the trial that established the avutometinib and defactinib combination for recurrent KRAS-mutant low-grade serous ovarian cancer.
Overview
Susana Banerjee is a consultant medical oncologist at The Royal Marsden and research lead for its gynaecology unit. She was first author of the 2025 Journal of Clinical Oncology report of RAMP 201, the phase 2 trial in which the RAF/MEK clamp avutometinib plus the FAK inhibitor defactinib produced responses in recurrent low-grade serous ovarian cancer, particularly KRAS-mutant disease, the basis of the combination's accelerated approval. She has led ESMO's gynaecological cancer guidelines and trials of PARP inhibitors.
Similar pages
not linked directly; found by shared links- PersonDavid M. Gershenson
Shares Low-grade serous ovarian cancer, Ovarian cancer and the tags ovarian, gynaecological, trialist.
- TrialA Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients
- PersonShannon N. Westin
Shares Ovarian cancer and the tags gynaecological, trialist.
- TrialRAMP 201
Shares RAMP 201: avutometinib with or without defactinib in recurrent low-grade serous ovarian cancer, Ovarian cancer.
- PersonMansoor Raza Mirza
Shares Ovarian cancer and the tags ovarian, trialist.
- TrialA Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
- PersonRobin L. Jones
Shares The Royal Marsden and the tag trialist.
- PersonKathleen N. Moore
Shares Ovarian cancer and the tags ovarian, trialist.